Speakers

Alexander Egle

Peter Fasching

Shabir Madhi

Shingai Mutambirwa

Simon J Nayler

Ryan Noach

Kristin N Smith

Patrick Soon-Shiong

Alvaro Urbano-Ispizua

Mark Verrill

Jean Botha

Bernardo Rapoport

Susana Banerjee

Georgia Demetriou

Chirantan Bose

Hope S. Rugo

Andrew Beggs

Alexander Eggermont

Dirk Arnold

Ross Camidge

Alexander Egle

Prof. Alexander Egle is a clinician as well as clinical scientist in Salzburg, Austria. He has a dual specialty as a hematologist/medical oncologist with a broad clinical, publication portfolio and an infectious disease specialty that focuses on HIV care and most recently COVID care. He has been heading the hematology outpatient clinic and infectious disease outpatient clinics in Salzburg for close to two decades. From early 2020, he coordinates the care of COVID patients in Salzburg. He has an interest and experience in COVID in the immunosuppressed, especially in lymphoid malignancies.”

Peter Fasching

Dr. Peter Fasching is an Associate Professor of Gynecology and Obstetrics Translational Medicine, at the University Hospital Erlangen and Comprehensive Cancer Center Erlangen-EMN, Germany. He obtained his MD degree at the University of Cologne, Medical School and in 2006 he earned his Board Certification in Gynecology and Obstetrics at University Hospital Erlangen. He was a Research Fellow at the Department of Hematology/Oncology, UCLA, Los Angeles.

Since 2011, he is the Head of the Clinical Trial Unit and Coordinator of the Breast Cancer Center and Gynecologic Oncology Center at the University Hospital Erlangen. He has served as Steering Committee member and Principal Investigator in several key breast cancer trials.

Dr. Fasching’s research focus is on big data, statistical modelling, genomics and systems biology.

Shabir Madhi

Shabir A. Madhi, M.B.B.C.H. (Wits), FCPaeds(SA), Ph.D.

Shabir Madhi is Dean of the Faculty of Health Sciences and Professor of Vaccinology at the University of the Witwatersrand, Johannesburg, South Africa; and co-founder and co-Director of the African Leadership Initiative for Vaccinology Expertise (ALIVE). Professor Madhi completed his undergraduate and postgraduate training at the University of the Witwatersrand, qualifying as paediatrician in 1996 and obtaining his PhD in 2003.

He currently also holds the positions of Director of the South African Medical Research Council Vaccines and Infectious Diseases Analytical Research Unit (VIDA) and is Research Chair in Vaccine Preventable Diseases of Department of Science and Technology/National Research Foundation. He currently serves as the Chair of the National Advisory Group on Immunization in South Africa and is a member of the WHO Strategic Advisory Group of Experts on Immunization (SAGE) since 2019.

Shabir has co-authored over 460 scientific publications since 1997. His research has focused on the epidemiology, and clinical development of lifesaving vaccines against pneumonia and diarrheal disease. Over the past decade, he has focussed on vaccines being developed for immunization of pregnant women for the benefit of the women and their young infants. He is leading the first two COVID-19 vaccine studies being undertaken in Africa.

Shingai Mutambirwa

 Prof. Shingai Mutambirwa holds M Med (Urology) Medunsa and FCS (Urol) degrees qualifying in 1996

Head of Department of Urology at Dr George Mukhari Academic hospital and Sefako Makgatho Health Sciences University in Pretoria South Africa since 2008 to date where he teaches post and under graduate medical/urology students.

Peer Reviewer for;  TheJournal of Urology (Official journal of the American Urological Association),  The African Journal of Urology,  Hindawi online publications

Published articles;

Over 80 peer reviewed articles and 10 book chapters.

Board Membership; The Prostate Cancer Foundation of South Africa (Founding member),Senator (Urology) for the Colleges of Medicine of South Africa (CMSA)

Advisory Boards/Key Opinion Leader for Aspen, Astellas, Jansen (J&J), Bayer, Schering Pharma, Pfizer, Eli Lilly, Abbott, Schering-Plough, Ferring, Adcock Ingram

Simon J Nayler

Simon J Nayler BSc MBBCh FFPath MMed is the Managing Partner and Consultant Histopathologist at the private laboratory of Drs Gritzman and Thatcher, a specialist cellular pathology laboratory in Johannesburg, South Africa. He has a joint appointment at the Wits Donald Gordon Medical Centre, the private practice of the University of the Witwatersrand Medical Faculty. He was previously Associate Professor in the Department of Anatomical Pathology at the University of the Witwatersrand. He is a previous president of the College of Pathologists of South Africa, past president of the Federation of South African Societies of Pathology, and current president of the Breast Interest Group of South Africa. His interests include soft-tissue, GIT, breast, uropathology and lung pathology, particularly with regard to molecular pathology and biomarkers.

He has published 50 journal articles in peer reviewed publications, two books chapters one on molecyular pathology. He has presented at numerous national and international meetings.

He is on adboards amongst other for MSD, Novartis, Roche.

Ryan Noach

Dr Ryan Noach is the Chief Executive Officer Discovery Health, appointed to this role in January 2020 after serving as Deputy CEO in the business for more than 5 years. Ryan joined Discovery Health in 2008 in the provider relations area, and became Chief Operating Officer of Discovery Health in 2009. During 2018 and 2019, Ryan was seconded to Discovery Bank, in the capacity of Deputy CEO of the Bank, to support the Banking team through the product finalization, build completion, business readiness and launch period. Ryan was previously the Chief Operating Officer and an Executive Director of the Netcare Hospital Group, having held various leadership roles across Netcare. His exposure to leadership in both the funding and provider sides of private healthcare, as well as more broadly in Banking and payments, unlocks useful insights.

Ryan qualified as a medical practitioner at Wits University in 1997 and pursued a post graduate career in emergency medicine and disaster management. He completed the Diploma in Primary Emergency Care and attended the Executive Development Program at GIBS Business School, University of Pretoria.

Ryan thoroughly enjoyed his exposure to Banking, maximizing the opportunity to learn a new field, and gain new skills, whilst leveraging his leadership and operational experience to contribute to the Bank.

Ryan has been consistently involved in various social and entrepreneurial causes throughout his adult life. Ryan is a proud father of 4 beautiful children, and in keeping with the Discovery Vitality culture, is an exercise and healthy nutrition fanatic.

Kristin N Smith

Program Manager for Fertility Preservation
Northwestern Robert H Lurie Comprehensive Cancer Center
Northwestern Center for Fertility and Reproductive Medicine

Kristin Smith, the Program Manager for Fertility Preservation, consults with all young, newly diagnosed oncology patients at Northwestern’s Lurie Cancer Center to help each patient understand their individual fertility risk associated with treatment as well as options for fertility preservation. She works extensively with young adult oncology survivors to help each patient explore their unique family building options and reproductive health post treatment. Kristin helps run the Oncofertility Professional Engagement Network (OPEN) of the Oncofertility Consortium by providing support across the world to providers who participate the network and also answers the national fertility hotline and email to triage patients for fertility preservation across the United States.

Patrick Soon-Shiong

MBBCh, MSc, FRCS (C), FACS.

Patrick Soon-Shiong, MD, is a surgeon, scientist, inventor, and philanthropist with over 500 issued worldwide patents and 100 scientific publications. He serves as Chairman and Chief Executive Officer of NantWorks, an ecosystem of companies with deep understandings in a wide variety of complex industries, from medical science to physics, from data to AI and from communications to mobility.

Under the NantWorks umbrella, Chairman of NantKwest, a Nasdaq-listed immunotherapy company focusing on natural killer cells; Executive Chairman of ImmunityBio, Inc., a biotechnology company focusing on vaccines and immunotherapy for cancer and infectious diseases; Chairman and CEO of NantHealth, a Nasdaq listed transformational healthcare company converging biomolecular medicine and bioinformatics with deep learning AI to empower physicians, patients, payers, pharma and researchers to transcend the traditional barriers of today’s healthcare system; Chairman of NantEnergy, a privately-held company accelerating the worldwide transformation to clean, reliable energy disrupting industrial scale methods of heat production, cement and plastics manufacturing; and Owner and Executive Chairman of California Times, publisher of two of the state’s largest newspapers, the Los Angeles Times and The San Diego Union-Tribune.

Dr. Soon-Shiong is also Chairman of the Chan Soon-Shiong Family Foundation and of the Chan Soon-Shiong Institute of Molecular Medicine, a nonprofit medical research organization.

Born and raised during apartheid in South Africa, Dr. Soon-Shiong has lived in Los Angeles since 1980 and is a citizen of the United States.

Alvaro Urbano-Ispizua

Director of the Hospital Clinic Institute of Hematology and Oncology, Clinical and
Provincial Hospital of Barcelona, Barcelona, Spain
Professor of Medicine, University of Barcelona, Barcelona, Spain

Dr Urbano-Ispizua areas of expertise are stem cell transplantation, cellular immunotherapy and haemato-oncology.

Dr Urbano-Ispizua previously served as the Head of the Research Unit of Cell Therapy and Stem Cell Transplantation at the Hospital Clinic of Barcelona, a unit which stands as one of the pioneers of bone marrow transplantation in Europe

Dr Urbano-Ispizua has authored and co-authored over 180 articles in internationally recognised, peer-reviewed journals such as Lancet, Journal of Clinical Oncology and Haematologica. He also serves a member of the editorial board of several journals

Mark Verrill

Dr Mark Verrill is a Consultant Medical Oncologist at the Northern Centre for Cancer Care, England.

After studying, he completed his training in medical oncology at the Royal Marsden Hospital and the Institute of Cancer Research. He took up his current NHS post in The Newcastle upon Tyne Hospitals Foundation Trust in 2007.

Mark has undertaken a number of management and leadership roles including Head of department of Medical Oncology, Lead Clinician for breast cancer in both Trust and Cancer Network, Chemotherapy lead for NCCC and the Northern Cancer Network, among others. He is also a member of the Executive Committee of the UK Breast Cancer Group.

Jean Botha

MBBCh (Wits); FCS (SA)

Discipline
Transplant Surgeon

Bernardo Rapoport

Professor Bernardo Rapoport is a Medical Oncologist at The Medical Oncology Centre of Rosebank since 1993. Professor Rapoport is an Extraordinary Professor , Department of Immunology, Faculty of Health Science, University of Pretoria. Professor Rapoport’s research efforts have focused on cancer supportive care, mainly febrile neutropenia and chemotherapy induced nausea and vomiting (CINV), breast cancer, lung cancer, melanoma, and more recently immuno-oncology. His clinical practice focuses on both solid tumours and haematological malignancies. Special interests include breast cancer, melanoma, lung cancer, immuno-oncology, immune checkpoint inhibitors and immuno-oncology biomarker research. He published extensively in this area in translational and clinical research.

Susana Banerjee

Dr Susana Banerjee is a Consultant Medical Oncologist and Research Lead for the Gynaecology Unit at The Royal Marsden NHS Foundation Trust and a Team Leader in Gynaecological Cancers (Systemic Therapy and Clinical Trials). Dr Banerjee specialises in ovarian cancer and advanced endometrial and cervical cancers.

Dr Banerjee graduated with a 1st class degree from St John’s College, University of Cambridge and completed her medical training at Royal Free Medical School, where she was a University of London Gold Medal Finalist.

Dr Banerjee was awarded an Avon Breast Cancer Crusade Clinical Fellowship for laboratory research and gained a PhD in 2009 from The Institute of Cancer Research, London. In 2007, she was awarded the San Antonio Breast Cancer Symposium Novartis Oncology Basic Science Award for her research.

Other prizes include the Association of Cancer Physicians McElwain Prize, Sir Antony Driver Prize (ICR) and Pfizer British Oncology Association Young Investigator Award (highly commended). She completed specialist medical oncology training at The Royal Marsden and was appointed a Consultant in 2011. In June 2015, she re-joined the ICR and gained the title of Reader in Women’s Cancers at the ICR in 2019.

Dr Banerjee has been part of national and international specialist groups, including the National Cancer Research Institute Gynaecological Cancers Clinical Studies Group, European Organization for Research and Treatment of Cancer (EORTC) Executive Steering Committee for Gynaecological Cancers, the European Society of Medical Oncology (ESMO) Gynaecological Cancers Faculty Faculty and ESMO Young Oncologists’ Committee.

She continues to be part of the ESMO Women for Oncology Committee and is Chair of the ESMO Resilience Task Force. Dr Banerjee, elected ESMO Director of Membership (2020-2022), serves on the ESMO Executive Board. She is a member of the Medical Advisory Board for the Ovacome UK charity.

She is actively involved in clinical trials and translational research. Her research interests include individualisation of patient treatment and targeted therapies in gynaecological cancers including rare malignancies. Dr Banerjee has active collaborations with other ICR teams – Professor Chris Lord (Gene Function Team), Dr Rachael Natrajan (Functional Genomics), Professor Jessica Downs (Epigenetics and Genome Stability) and Professor Udai Banerji (Clinical Pharmacology and Trials).

She supervises MD(Res) and PhD students. Dr Banerjee is UK and Global Chief Investigator for a number of national and international clinical trials.

Georgia Demetriou

Professor Georgia Demetriou
Medical Oncologist
Specialist Physician
Certificate in Medical Oncology College of Medicine South Africa
Fellow of the College of Physicians South Africa
MBBCh University of the Witwatersrand

Prof Georgia Demteriou is a Medical Oncologist in Johannesburg, South Africa.

She is the Academic Head of Medical Oncology and Senior Lecturer at the University of the Witwatersrand Johannesburg, and the acting Head of the Department of Medical Oncology at the Charlotte Maxeke Johannesburg Academic Hospital. Prof Demetriou is the head of the Medical Oncology Clinical trial Syndicate of the Wits Clinical Trial Unit at the Wits Health Consortium and a Medical Oncologist in Private Practice at the Wits Donald Gordon Medical Centre in Parktown Johannesburg.

In addition to her role as Medical Oncologist she ran a General Medicine Teaching Unit at the Charlotte Maxeke Hospital for 10 years. Prof Demetriou has been the intern and community service medical officer curator at the Charlotte Maxeke Johannesburg Academic Hospital since 2007, overseeing the 130 junior medical staff at the hospital. She is an examiner for undergraduate medical students at the University of the Witwatersrand and a post graduate examiner and convenor for The College of Medicine in the field of Medical Oncology, also serving as an examiner and organizer in Internal Medicine .

She is a Director and Chairperson of the South African Oncology Consortium (SAOC) Board. She is an Executive Committee member of the South African Medical Oncology Society and serves as the treasurer of the Society since 2009.

She has been involved in numerous pivotal clinical trials in the area on Oncology as local Principle Investigator, National Principle Investigator and serves on local and international Advisory Boards with a particular interest in Female malignancies, Onco-Fertility and GI malignancies. She has published in local and international journals in her field of interest.

Chirantan Bose

Education
  • MBBS
  • MD Pathology (2006)
  • Diploma in Clinical Genetics (Univ of South Wales UK)
  • Training in Molecular Oncology  (Univ of Pittsburgh Medical Centre USA)
  • MBA IIT Bombay (Shailesh J Mehta School of Management)
  • MBA Olin Business School – Washington University
Experience
  • Hematopathologist – Dr Lal Path Labs Delhi
  • Laboratory Director – American Institute of Pathology and American Oncology Institute
  • Vice President – Oncology Services – Medgenome Labs
  • National Head – Flowcytometry – Beckman Coulter
  • Senior Vice President – Lab Operations – Healthians
  • Director – Patient Care Service – Datar Cancer Genetics, India, UK, Germany (Current position)

Hope S. Rugo

Hope S. Rugo, MD, FASCO Professor of Medicine Director, Breast Oncology and Clinical Trials Education UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, CA

Hope S. Rugo, MD, FASCO, is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at University of California San Francisco (UCSF) in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer. She entered the field of breast cancer in order to incorporate novel therapies based on an understanding of the biology of cancer with excellent quality of care into the treatment of women with breast cancer.

Dr. Rugo is the Director of Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center. She is a principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early and late stage breast cancer, and has published widely in this area. Her current research interests include immunotherapy and combinations of targeted agents in the treatment of breast cancer to overcome resistance. In addition, Dr. Rugo has conducted a number of studies focusing on reducing toxicity from therapy, resulting in approval of scalp cooling to reduce chemotherapy induced hair loss, and a steroid mouthwash to reduce targeted agent stomatitis. She is an investigator and the chair of the Safety Committee for the multicenter adaptively randomized phase II I-SPY2 trial, and also serves on the Novel Agents Committee. Dr. Rugo is the co-chair of the Triple Negative Working Group and an active member of the Translational Breast Cancer Research Consortium (TBCRC), and is the principal investigator of several TBCRC trials including a multi-center immunotherapy trial funded by the Breast Cancer Research Foundation (BCRF). She is an active member of the Alliance (formerly CALGB) Breast Committee, as well as ASCO, where she serves on the Guidelines Committee and as an editor for the Education Committee.

In addition to her research, Dr. Rugo is an active clinician, and is committed to education, regularly lecturing locally, nationally, and internationally on subjects relating to the treatment of and supportive care for breast cancer. At UCSF, Dr. Rugo runs the Breast Forum, an open bimonthly evening educational session for breast cancer patients, families, and friends from throughout the bay area. Dr. Rugo graduated from the University of Pennsylvania School of Medicine in 1983. She completed a residency in internal medicine and primary care followed by a fellowship in hematology and oncology at the University of California San Francisco. She was a post-doctoral fellow in immunology participating in laboratory research at Stanford University from 1988-1990. In 1990, Dr. Rugo joined the faculty at UCSF in the Division of Hematology and Oncology. Dr. Rugo has been recognized for her excellence in both patient care and in teaching of both medical students and training physicians. She has received several awards including the Bank of America Giannini Foundation Award and a UCSF Clinical Cancer Center Investigator Research Program intra-mural award. In 2006, she was honored for her work in Breast Cancer Research by the Friends of the Breast Care Center.

Andrew Beggs

Co-Lead – Molecular Oncology, Pathology and Genetics, Professor in Surgery & Cancer Genetics
  • Head of West Midlands GI & Gynaecology Cancer Tumour Board
  • Cancer Research UK & RCSEng Advanced Clinician Scientist, Consultant Colorectal & General Surgeon
Prof. Beggs major research interests include colorectal, oesophageal and sarcoma cancer biology and translational medicine. He has published articles in The Lancet, Gut, Journal of Pathology and PLoS Genetics. Collaborated in writing the European consensus guidelines for the management of Peutz-Jeghers syndrome.

Alexander Eggermont

Professor Alexander Eggermont has been Professor of Oncology with the status of «Classe Exceptionelle» in the Paris-Sud University since 2012 and Professor of Oncological Surgery at the Erasmus University of Rotterdam (Holland) since 2003. He also holds a Chair in the international research network on cancer at the Erasmus University of Rotterdam and since 2001 he has filled the Joseph Maisin Honorary Chair of Oncological Surgery at the Louvain Catholic University (Belgium). From 2000 to 2011 he was Head of the Oncological Surgery Department of the Daniel den Hoed University Cancer Centre in Rotterdam.

During his career, he chaired the EORTC (European Organization for Research and Treatment of Cancer) from 2003 to 2006 and ECCO (European CanCer Organization) from 2008 to 2010. He is currently President of the European Academy of Cancer Sciences.

He is a surgeon and holds a doctorate in Tumour Immunology which he obtained in 1987 at the Erasmus University of Rotterdam. He specialised in research in immunotherapy and the treatment of melanomas and sarcomas in addition to fundamental research in pathogenesis and immunology of tumours. He has been awarded many prizes in recognition of his work in the treatment of cancer.He was elevated to the status of Chevalier of the Légion d’Honneur by the french Ministry of Foreign Affairs and International Development on 1st January 2015.

Dirk Arnold

Dirk Arnold undertook specialist training at Charité, Humboldt University in Berlin. Subsequently, he trained as a medical oncologist and specialist in palliative care at the Martin Luther University Halle-Wittenberg in Halle, Germany. He has held the positions of Professor and Chair of the Gastrointestinal Cancer Unit at the Martin Luther University Halle-Wittenberg. In 2010, he was appointed as Professor for Oncology at University Hamburg, and held the position as Director of the University Cancer Center Hamburg. In 2015, he additionally got appointed as Director of oncology services at the Instituto CUF de Oncologia in Lisbon, Portugal. Since 2017, Professor Arnold is Director of Asklepios Tumorzentrum Hamburg, a large network cancer centre, and chairman of the Oncology Department at AK Altona, Hamburg.

His main research interests include the treatment of gastrointestinal and genitourinary cancers, specifically in molecular-targeted therapies, immunotherapy, multimodal treatment strategies and early drug developments. He is also interested in research network structures and methodology of clinical research and benefit evaluation procedures, as well as in palliative and supportive care.

Professor Arnold served as Chairman of the Colorectal Cancer Study Group of the Working Group for Internal Oncology (Arbeitsgemeinschaft Internistische Onkologie [AIO]). He is a key member of several German and other international cancer societies, including the European Society for Medical Oncology (ESMO), where he serves as a Council Member and Chairman of the Compliance Committee. He served as Section Editor for GI Cancers in the Guideline Committee and at Annals of Oncology. He is also a Co-Chairman of the Task Force on Colorectal Cancer and the board of the Gastrointestinal Cancer Study Group of the European Organisation for Research and Treatment of Cancer (EORTC). Dr Arnold has co-authored more than 230 articles in peer-reviewed journals and more than 600 abstracts at international/national meetings.

Ross Camidge

Director of Thoracic Oncology,
Joyce Zeff Chair in Lung Cancer Research
University of Colorado Cancer Centre, Denver, USA

Following a PhD in Molecular Biology at the Medical Research Council’s Laboratory of Molecular Biology at Cambridge University, UK, Dr Camidge completed his medical training at Oxford University, UK. He then became the first person to double train in Medical Oncology and Clinical Pharmacology in the UK, before joining the University of Colorado, USA from October 2005.

Dr Camidge’s main clinical and research interests are thoracic malignancies and developmental therapeutics. The discoveries he and his team have made have changed the standard of care for the treatment of lung cancer multiple times. He has authored over 300 academic publications, including in the Journal of Thoracic Oncology, Lancet Oncology, and New England Journal of Medicine. He has received numerous awards including in 2012, the Bonnie J. Addario International Lectureship Award for which he was credited as a ‘Luminary in the quest to eradicate lung cancer’. In 2013 he became the first physician to receive the Hank Baskett Sr. Spirit Award, for which he was credited as being ‘one of the leading minds in lung cancer today’. In 2014, he was nationally recognized by The Quality of Life Center at Claremont University in California as an ‘Exemplary mentor in the positive development of junior colleagues in the profession’. In 2016, the Lung Cancer Foundation presented him with the Breath Away From The Cure Award describing him as ‘Simply one of the best in treating lung cancer today’.

Every year since 2017, he has been internationally recognized as a highly cited researcher ranked in the top 1% of all of Clinical Medicine by Clarivate Analytics Web of Science. In 2019 and 2020 he was ranked at the ‘World Expert’ level by Expertscape and recognized to be in the top 0.0043% of scholars writing about Lung Neoplasms over the past 10 years. He is also the National Medical Director of the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC) – a collaborative network of 15 US and Canadian sites conducting trials in thoracic oncology, Co-chair of the Elsevier ClinPath (formerly VIA) Oncology Lung Cancer Pathways Committee and a past-member of the National Comprehensive Cancer Network Lung Cancer Committee.